Navigation Links
Pair of microRNA molecules controls major oncogene in most common leukemia

cording to Pekarsky. Earlier this year the investigators provided the first direct evidence that over-expression of an miRNA molecule could result in development of cancer have since identified a number of miRNAs associated with B-cell chronic lymphocytic leukemia that appear to promote tumor development. But the protective miR-29 and miR-181 molecules are emerging as the most important miRNAs discovered to date, Pekarsky said. "MicroRNAs such as these could prove to be as powerful as the protein transcription factors that we know can turn genes on and off," he said.

The researchers studied TCL1 expression and miRNA expression in 23 samples of indolent B-CLL, 25 samples of aggressive B-CLL, and 32 samples of B-CLL exhibiting a chromosomal deletion, which makes it the most difficult type to treat. They found that TCL1 over-expression correlated with the two most aggressive forms of the cancer. To determine which miRNAs targeted TCL1, they used microRNA-microchips and elaborate computer programs to identify miR-29 and miR-181.

Regulation of TCL1 expression by these two miRNAs is relevant to all the three groups of cells studied, Pekarsky said. "You can look at the miRNA profile and say whether the cancer is aggressive or indolent," he said. And of the two miRNAs, miR-29 offers the most predictive power, Pekarsky added.

"We have a lot of work to do to characterize these miRNAs because we don’t even know whether they work on transcriptional or translational level," he said. "But finding that they control this cancer’s major risk factor is a very helpful advance."
'"/>

Source:American Association for Cancer Research


Page: 1 2

Related biology news :

1. NYU, Rockefeller researchers find complexity of regulation by microRNA genes
2. Molecular steps involved in the creation of gene-silencing microRNAs identified
3. Scientists find microRNAs regulate plant development
4. Role of microRNA identified in thyroid cancer
5. Twin molecular scissors link creation of microRNAs with gene-silencing
6. Single microRNA causes cancer in transgenic mouse
7. Activation of microRNA inhibits cancer gene in human cancer cells
8. Unicellular microRNA discovery
9. Xie Lab demonstrates the role of microRNA pathway
10. Inflammatory molecules released by pollen trigger allergies
11. Medical molecules designed to respond to visible light that can penetrate tissue

Post Your Comments:
(Date:11/23/2009)... Two new studies reveal in unprecedented detail h...assemble new proteins and guide them toward their ...molecular dynamics flexible fitting (MDFF) to exam...nent molecular partners. , The first study, in ... concerns the intimate signaling between the ribos...
(Date:11/23/2009)...stitute of General Medical Sciences (NIGMS), part ...esting $42.3 million for grants in scientific area... developed the GO grant program to stimulate biome...d by the American Recovery and Reinvestment Act (R...t promise to have a significant impact on a field ...
(Date:11/23/2009)...s available in German . , A bit of imaginat... be a bad thing. It could help to add data from ar...ever, it must do so constructively. In order to in...th more than just imagination, physicists at the M...ed a theory of spatial perception called informati...
Breaking Biology News(10 mins):Computational microscope peers into the working ribosome 2Computational microscope peers into the working ribosome 3NIGMS invests in scientific Grand Opportunities with Recovery Act funds 2NIGMS invests in scientific Grand Opportunities with Recovery Act funds 3Visual assistance for cosmic blind spots 2Visual assistance for cosmic blind spots 3Visual assistance for cosmic blind spots 496 Week Safety and Efficacy Findings Presented for INTELENCE 28TM 29 28etravirine 29 As Part of HIV Combination Therapy 52098 196 Week Safety and Efficacy Findings Presented for INTELENCE 28TM 29 28etravirine 29 As Part of HIV Combination Therapy 52098 296 Week Safety and Efficacy Findings Presented for INTELENCE 28TM 29 28etravirine 29 As Part of HIV Combination Therapy 52098 396 Week Safety and Efficacy Findings Presented for INTELENCE 28TM 29 28etravirine 29 As Part of HIV Combination Therapy 52098 496 Week Safety and Efficacy Findings Presented for INTELENCE 28TM 29 28etravirine 29 As Part of HIV Combination Therapy 52098 596 Week Safety and Efficacy Findings Presented for INTELENCE 28TM 29 28etravirine 29 As Part of HIV Combination Therapy 52098 6New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U S HIV Clinical Studies 52096 1New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U S HIV Clinical Studies 52096 2New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U S HIV Clinical Studies 52096 3New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U S HIV Clinical Studies 52096 4New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U S HIV Clinical Studies 52096 5New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U S HIV Clinical Studies 52096 6New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U S HIV Clinical Studies 52096 7New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U S HIV Clinical Studies 52096 8New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine 28TDF FTC 29 Versus Boosted Protease Inhibitor Regimen of Atazanavir Rito 4747 1New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine 28TDF FTC 29 Versus Boosted Protease Inhibitor Regimen of Atazanavir Rito 4747 2New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine 28TDF FTC 29 Versus Boosted Protease Inhibitor Regimen of Atazanavir Rito 4747 3New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine 28TDF FTC 29 Versus Boosted Protease Inhibitor Regimen of Atazanavir Rito 4747 4New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine 28TDF FTC 29 Versus Boosted Protease Inhibitor Regimen of Atazanavir Rito 4747 5New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine 28TDF FTC 29 Versus Boosted Protease Inhibitor Regimen of Atazanavir Rito 4747 6
...ch Professor Benjamin Cravatt, Ph.D., is being pub...Biological Chemistry. , The new study describes a ...d-for the biosynthesis of neurotransmitter lipids,...dogenous cannabinoid ("endocannabinoid") anandamid...(Abh4) in areas such as the central nervous system...
...righteningly large if only there was a greater con...udes. The study adds support to the theory that so...oic period because they had a much richer oxygen s...er. , The study, "No giants today: tracheal oxygen...presented Oct. 10 and 11 at Comparative Physiology...
...earch-and-destroy quest for weeds, will soon be mo... fields at the University of Illinois. What,s more...ile significantly reducing herbicide use. , The ro...ll cameras mounted on a frame on top of the machin...human, said Lei Tian, agricultural engineer at the...
Other Biology News:Nanotechnology propels advances in regenerative medicine research 2Giant insects might reign if only there was more oxygen in the air 2Giant insects might reign if only there was more oxygen in the air 3New system could drastically reduce herbicide use 2New system could drastically reduce herbicide use 3
(Date:11/20/2009)...re/ -- Veridiam (www.veridiam.com) won the prestig...y at the 2009 Workplace Excellence Awards. The awa...an Resources Management and recognize innovative a...ridiam was one of nine winners, selected from more... the recent awards ceremony. San Diego-based Verid...
(Date:11/20/2009)...RNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NV...itten public offering of 6,800,000 shares of its c...share. The approximately $21 million of net proce...d commissions, will be used for preclinical studie...nternal research and development programs, working...
(Date:11/20/2009)...wire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (...th Circuit Court of Appeals reversed a U.S. Distri...d to pursue all of its claims against The Lash Gro...r trial. CTI filed a complaint against The Lash G...ltant for CTI,s product TRISENOX, in 2007 seeking ...
(Date:11/20/2009)...O recently announced that Dr. Dominique Hebrault w...cess Analytical Technology (PAT) in Green Chemistr.... , (PRWEB) November 20, ... Technology (PAT) in Green Chemistry and Green Eng...l Technology (PAT) case studies will be presented ...
Breaking Biology Technology:Veridiam Wins Workplace Excellence Crystal Award in Mid-Size Company Category 2Novavax Prices Public Offering of Common Stock 2Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group 2Process Analytical Technology (PAT) in Green Chemistry and Green Engineering 2
...yne, Inc.,(Nasdaq: RDYN ) announced today that it...2008 at 4:45 P.M. ET to report first quarter 2008,... Replidyne will host its,annual shareholder meetin...n Louisville, CO., Earnings conference call in...resident and CEO, and other members of Replidyne,s...
...Points from the First Quarter of 2007 to ...to Launch Newest Generation of Laser Lipolysis ...Mass., April 29 Cynosure, Inc.,(Nasdaq: CYNO ), ...ray of,light-based aesthetic treatment systems, to... the quarter ended March 31, 2008., First-Quarter...
...merica,Inc. (OTC Bulletin Board: CBAI), the umbili...tp://www.cordblood-america.com ) focused on,bring...ilies nationwide and,internationally, today report...erview with Francis Gaskins, said 2007 acquisition...d a 600 percent increase in gross profits., "We w...
Other Biology Technology:Replidyne to Report First Quarter 2008 Earnings 2Replidyne to Report First Quarter 2008 Earnings 3Cynosure Reports 41% Revenue Increase: 10th Consecutive Quarter of Revenue Growth 2Cynosure Reports 41% Revenue Increase: 10th Consecutive Quarter of Revenue Growth 3Cynosure Reports 41% Revenue Increase: 10th Consecutive Quarter of Revenue Growth 4Cynosure Reports 41% Revenue Increase: 10th Consecutive Quarter of Revenue Growth 5Cynosure Reports 41% Revenue Increase: 10th Consecutive Quarter of Revenue Growth 6Cynosure Reports 41% Revenue Increase: 10th Consecutive Quarter of Revenue Growth 7Cynosure Reports 41% Revenue Increase: 10th Consecutive Quarter of Revenue Growth 8Cynosure Reports 41% Revenue Increase: 10th Consecutive Quarter of Revenue Growth 9Cynosure Reports 41% Revenue Increase: 10th Consecutive Quarter of Revenue Growth 10Cynosure Reports 41% Revenue Increase: 10th Consecutive Quarter of Revenue Growth 11Cord Blood America CEO Matthew Schissler Says Operations Significantly Streamlined 2
Streptavidin, PE conjugated/tagged from Invitrogen
Supercoiled DNA Ladder from Invitrogen
GIBCO RPMI Medium 1640; powder from Invitrogen
Rabbit Anti-Human Parathyroid Hormone Receptor 2 Polyclonal Antibody, Unconjugated from Abcam
Biology Products: